Cardiorenal benefits of mineralocorticoid antagonists in CKD and type 2 diabetes
Cardiorenal benefits of mineralocorticoid antagonists in CKD and type 2 diabetes
About this item
Full title
Author / Creator
Publisher
Munich: Springer Nature B.V
Journal title
Language
English
Formats
Publication information
Publisher
Munich: Springer Nature B.V
Subjects
More information
Scope and Contents
Contents
Diabetic kidney disease (DKD) develops in almost half of all patients with diabetes and is the most common cause of chronic kidney disease (CKD) worldwide. Despite the high risk of chronic renal failure in these patients, only few therapeutic strategies are available. The use of renin–angiotensin system blockers to reduce the incidence of kidney fa...
Alternative Titles
Full title
Cardiorenal benefits of mineralocorticoid antagonists in CKD and type 2 diabetes
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2719589083
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2719589083
Other Identifiers
ISSN
0340-9937
E-ISSN
1615-6692
DOI
10.1007/s00059-022-05138-2
